Priovant Therapeutics
Tracked across 2 events · 23 articles · First seen Apr 02, 2026 · Last active Aug 26, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Priovant Therapeutics is the developer of brepocitinib and the sponsor of the VALOR trial. The publication of positive skin-specific outcomes enhances the drug's clinical profile and supports its regulatory and commercial prospects.
Aug 26, 2026 · 7 articles
Business
Impact: Priovant Therapeutics, a subsidiary of Roivant Sciences, is expanding its brepocitinib development program into lichen planopilaris, which is a positive development for the company.
Apr 02, 2026 · 16 articles
ERGEN INTELLIGENCE
Track Priovant Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard